eTheRNA immunotherapies is a clinical-stage Belgian biotech company applying mRNA based immunotherapies for the treatment of cancer and infectious diseases.
eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy.
In March 2016, eTheRNA immunotherapies secured EUR 24 million in a Series A investment with a strong international syndicate of investors. In 2017, eTheRNA relocated to Niel, near Antwerp, Belgium, where a cGMP-compliant mRNA manufacturing laboratory was inaugurated in October 2018.
eTheRNA immunotherapies is a clinical-stage Belgian biotech company applying mRNA based immunotherapies for the treatment of cancer and infectious diseases. eTheRNA’s goal is to commercialize these immunotherapies to deliver long lasting clinical remission to cancer patients.